Related Experiment Videos
Molecular pathology in oncology--the AstraZeneca perspective
David A Campbell1, James Carmichael, Rajesh Chopra
1Experimental Medicine, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. david.campbell@astrazeneca.com
Pharmacogenomics
|December 9, 2004
Summary
AstraZeneca is integrating genetics and genomics into oncology research and development. This strategy aims to improve targeted cancer therapies through patient stratification and novel biomarker discovery.
Area of Science:
- Oncology
- Genetics
- Genomics
Background:
- The oncology portfolio's growth is strategically important for AstraZeneca.
- Targeted cancer therapies require a deep understanding of molecular pathology.
- Advances in genetics and genomics are transforming cancer research.
Purpose of the Study:
- To enhance AstraZeneca's oncology R&D platform using new genetic and genomic technologies.
- To leverage pharmacogenetics and pharmacogenomics for future oncology products.
- To identify novel biomarkers and diagnostics for streamlining R&D.
Main Methods:
- Utilizing genetics and genomics for patient identification and stratification.
- Exploring pharmacogenetics and pharmacogenomics in oncology drug development.
- Focusing on understanding the biological basis of cancer diseases.
Main Results:
- Future AstraZeneca oncology products will increasingly depend on genetic and genomic data.
- These technologies will yield novel biomarkers and diagnostics.
- The approach aims to streamline R&D and deepen disease understanding.
Conclusions:
- Integrating genetics and genomics is vital for advancing targeted cancer therapies.
- Practical challenges in applying these technologies and healthcare infrastructure need addressing.
- Clinical studies are essential for validating the pharmacogenetics and pharmacogenomics approach.